Fulcrum Therapeutics, Inc. Research And Development Expense

• Fulcrum Therapeutics, Inc. showed a decrease of -11.5% in Research And Development Expense from 2024 to 2025.
• This data is from Fulcrum Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Fulcrum Therapeutics, Inc.'s Research And Development Expense has grown by 122.8%.
• Historical annual values: Fiscal year 2025: $56.10 million | Fiscal year 2024: $63.39 million | Fiscal year 2023: $71.80 million | Fiscal year 2022: $76.78 million | Fiscal year 2021: $69.70 million | Fiscal year 2020: $59.04 million | Fiscal year 2019: $71.07 million | Fiscal year 2018: $25.18 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026